Rightway has raised a $155 million Series E to expand a pharmacy-benefit business designed not to earn more when prescription prices rise. The company administers drug benefits for employers and gives covered workers clinical help choosing medicines and navigating care.

Its service team includes pharmacists and certified pharmacy technicians trained on each employer’s plan. They answer benefit and medication questions and guide members toward clinically appropriate, lower-cost drugs. A broader care-navigation product helps people find providers and make use of their health benefits.

The economic pitch rests on what Rightway says it doesn’t retain. It bills clients a per-member administrative fee, returns manufacturer rebates, keeps none of the spread between a health plan’s payment and a pharmacy’s reimbursement, collects no dispensing revenue and owns no pharmacies.

SureSpend turns that fee model into a budget commitment. Rightway uses an employer’s past claims and expected usage to establish a monthly per-member spending ceiling, then settles up every quarter: an overrun triggers a full refund, while an underrun stays with the client. For GLP-1 and rare high-cost drugs, the company says prices reflect its net cost and rebates go back to the plan.

Rightway says 45 Fortune 500 companies now run their pharmacy benefits through its platform and that it covers millions of people. In its account of Tyson Foods, an early large client, the company attributed $6 million of savings to switching members to biosimilar drugs.

Francisco Partners led the financing, with existing investors Thrive Capital and Khosla Ventures participating. Rightway plans to spend the proceeds on technology that removes administrative work from pharmacists, identifies cost and care opportunities earlier, and gives employers and members more flexibility in how prescriptions are managed and filled.